

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

Anti-2019-nCoV S-mIgG1 Neutralizing Antibody (8A5) EBT-EPT084

Article Name	Anti-2019-nCoV S-mIgG1 Neutralizing Antibody (8A5)
Biozol Catalog Number	EBT-EPT084
Supplier Catalog Number	EPT084
Alternative Catalog Number	EBT-EPT084-50
Manufacturer	ELK Biotechnology
Category	Proteine/Peptide
Product Description	The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-...

Application Notes

Biological activity: Immobilized Anti-2019-nCoV S-mIgG1 Antibody (8A5)(CatDA035) at 2µg/ml (100 µl/well) can bind 2019-nCoV S Protein RBD-Fc(CatDRA126). The ED50 of 2019-nCoV S Protein RBD-Fc(CatDRA126) is 5.95 ng/ml. Background: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It has been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity